Is Bristol Myers Squibb a Value Trap at $60? Analyzing Patent Cliffs and Future Prospects

Bristol Myers Squibb at a Glance

Bristol Myers Squibb (NYSE: BMY) currently trades just under $60 per share, a price that might seem enticing for a pharmaceutical giant with a robust pipeline and established blockbuster drugs. However, value investors are increasingly questioning whether this stock is truly undervalued or is instead a value trap waiting to spring. The core concern centers around the company's looming patent cliffs, which threaten to erode revenue from its two best-selling medicines by the end of the decade.

Patent Cliffs and Growth Concerns

A patent cliff occurs when a drug loses its patent exclusivity, opening the door for generic competitors that can drastically reduce sales. Bristol Myers faces significant cliffs for its cancer immunotherapy Opdivo and its anticoagulant Eliquis (the latter developed in partnership with Pfizer). These two drugs together account for a substantial portion of the company's revenue, making their impending loss a serious concern for long-term growth.

Opdivo and Eliquis: The Two Pillars at Risk

Opdivo (nivolumab) is a PD-1 inhibitor used to treat various cancers, including melanoma, lung cancer, and kidney cancer. Its patent is set to expire in the mid-2020s, and while Bristol Myers is developing next-generation immunotherapies, none have yet demonstrated the same blockbuster potential. Eliquis (apixaban) is a direct oral anticoagulant widely prescribed for atrial fibrillation and venous thromboembolism. Its patent protection extends into the late 2020s, but after that, generic competition could slash sales by over 80%, as seen with other anticoagulants.

Learn more about Opdivo and Eliquis specifics.

Is the Stock Overvalued? A Value Investor's Perspective

At $60, Bristol Myers has a price-to-earnings (P/E) ratio of around 10, which historically indicates a bargain. However, this low P/E reflects the market's skepticism about future earnings declines. When patent cliffs hit, earnings per share (EPS) can drop sharply, making the stock seem cheap today but potentially expensive once forward earnings are adjusted downward.

Value investors typically look for companies with sustainable competitive advantages. Bristol Myers does have a pipeline of new drugs, including treatments for cardiovascular disease, fibrosis, and cancer. Yet many of these are early-stage or face stiff competition. The company's ability to launch enough new products to offset revenue losses from Opdivo and Eliquis remains uncertain.

Comparing to Peers

When compared to pharmaceutical giants like Pfizer or Merck, Bristol Myers shows a lower P/E but also a higher dependency on a concentrated drug portfolio. A 2023 analysis by industry analysts suggests that while BMY's current valuation is depressed, it may not account for the full magnitude of the patent cliff impact. Investors should consider not just the current price but the revenue trajectory over the next five years.

Conclusion: Should Value Investors Take a Second Look?

Bristol Myers Squibb presents a classic value conundrum: a low price relative to current earnings, but with significant headwinds that could depress future earnings. For long-term value investors, the key is to assess whether the pipeline and cost-cutting measures can bridge the gap. The company has a strong dividend yield (around 4.5%) and ongoing share buybacks, which provide some downside protection.

Ultimately, Bristol Myers may not be a wealth destroyer, but it could underperform the broader market if the patent cliffs materialize without sufficient offsetting growth. A prudent approach would be to monitor the company's clinical trial results and regulatory progress for new drugs. For now, the stock at $60 is a cautious buy for those who believe in the pipeline, but a potential value trap for those who overestimate its near-term growth.

• Consider the risk of patent cliffs for Opdivo and Eliquis.
• Evaluate the pipeline's potential to replace lost revenue.
• Assess the dividend yield as a buffer against price volatility.

Disclosure: The author does not hold a position in BMY. This article is for informational purposes only and does not constitute investment advice.

---

Opdivo and Eliquis Detail: Opdivo's patent expires in the mid-2020s; biosimilar competition is expected. Eliquis loses patent protection around 2028, bringing in generics.

Peer Analysis: Compare BMY's P/E and revenue concentration with Pfizer (PFE) and Merck (MRK). See industry reports for details.